CARsgen Reveals Updated Satri-Cel Research Updates at ASCO GI 2024

Study reportedly demonstrates the encouraging safety profile of satri-cel, the first autologous Claudin18.2 CAR T cell therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *